Company shares are trading at $6.89 significantly above $6.03, the stock’s 50 day moving average and impressively higher than the 200 day moving average of $6.03. The 50 day moving average moved up $0.86 whereas the 200 day moving average was up $0.86 or +14.28%. 1,547K shares changed hands in the last trading session. Volume was up 90.41% over the stocks average daily volume.
Investors are a little more bullish of late if you look at the fall in short interest. The company saw a fall in short interest between September 15, 2017 and September 29, 2017 of -2.43%. Short shares fell from 6,090,418 to 5,942,552 over that period. Days to cover increased 4.0 to 16.0 and the percentage of shorted shares is 0.10% as of September 29.
The following firms have recently changed their position in VRAY. As of quarter end Acuta Capital Partners, LLC had bought a total of 85,314 shares growing its position 14.2%. The value of the company’s investment in ViewRay, Inc. went from $4,637,000 to $4,441,000 a change of $196,000 since the last quarter. Ubs Group Ag bolstered its holdings by buying 1,071 shares an increase of 525.0% as of 06/30/2017. Ubs Group Ag currently owns 1,275 shares with a value of $8,000. The value of the position overall is up by 300.0%.
As of the end of the quarter Vantage Investment Advisors, LLC had acquired 4,000 shares growing its holdings by 133.3%. The value of the total investment in ViewRay, Inc. increased from $26,000 to $45,000 a change of 73.1% quarter over quarter. Quantitative Systematic Strategies LLC added to its investment by buying 2,967 shares an increase of 28.1%. Quantitative Systematic Strategies LLC owns 13,531 shares valued at $78,000. The total value of its holdings increased 16.4%.
Mizuho began coverage of the stock with an initial rating of “Buy”.
As of the last earnings report the EPS was $-1.27 and is estimated to be $-0.82 for the current year with 59,007,000 shares now outstanding. Next quarter’s EPS is forecasted to be $-0.05 with next year’s EPS anticipated to be $-0.29.
ViewRay, Inc., launched on October 6, 2013, through its subsidiary ViewRay Technologies, Inc., designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Business’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered..